Evidence map›Paper›PMID 26728188›Full record

ReviewCurrent pain and headache reports2016

Update on the Pharmacological Treatment of Chronic Migraine.

Christina Sun-Edelstein, Alan M Rapoport

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pain and headache reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives.Frontiers in pain research (Lausanne, Switzerland) · 2021
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Treatment of the Patient with Refractory Headache.Current pain and headache reports · 2018
    Review
  13. Treatment Update of Chronic Migraine.Current pain and headache reports · 2017
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Christina Sun-EdelsteinDepartment of Medicine, St Vincent's Hospital, The University of Melbourne, Melbourne, Australia. Christina.Sun-Edelstein@svha.org.au.
Alan M RapoportThe David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. alanrapoport@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic migraine (CM) is a common and disabling disorder that remains underdiagnosed and poorly treated. Significant unmet therapeutic needs add to the burden of this disorder; even when CM is recognized, effective treatment options are limited and randomized controlled trials supporting the use of various preventive medications are sparse. In this review, we discuss the available options for CM treatment. Currently the only FDA-approved treatment for CM prevention is onabotulinumtoxinA. Two double-blind studies have demonstrated the efficacy of topiramate for CM prevention, but it is not FDA-approved for this indication. Treatments in development for migraine will also be reviewed. Advancements in the understanding of migraine pathogenesis have identified new targets for both acute and preventive treatment and have engendered the development of targeted and mechanism-based therapies. The need for more effective treatment for CM patients, which has long since been identified, is now being addressed. Several of the emerging treatments for migraine prevention are under investigation specifically for CM or high-frequency episodic migraine.

Indexed as

AnimalsBotulinum Toxins, Type AChronic DiseaseFructoseHumansMigraine DisordersNeuroprotective AgentsTopiramateTreatment OutcomeBotulinum Toxins, Type AFructoseNeuroprotective AgentsTopiramateChronic migraineEmerging migraine treatmentsMigraine treatmentMonoclonal antibodies to CGRP or its receptorOnabotulinumtoxinATopiramate

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.